Cyclooxygenase-2-dependent prostacyclin formation is regulated by low density lipoprotein cholesterol in vitro.

Smith LH, Boutaud O, Breyer M, Morrow JD, Oates JA, Vaughan DE
Arterioscler Thromb Vasc Biol. 2002 22 (6): 983-8

PMID: 12067908 · DOI:10.1161/01.atv.0000019734.89917.35

Reduction of plasma low density lipoprotein (LDL) levels is associated with a reduced risk of myocardial infarction, stroke, and death. Some of this clinical benefit may be derived from an improvement in endothelium-dependent vasodilation. In the present study, we examined the effects of LDL reduction on cyclooxygenase (COX) activity and prostacyclin (PGI2) production. Human umbilical vein endothelial cells exposed to reduced concentrations of LDL demonstrated increased PGI2 production in a dose-dependent manner (from 0.75+/-0.2 to 2.6+/-0.2 ng/mL, P<0.0001). This alteration in PGI2 production did not result from LDL-induced changes in PGI2 synthase expression. However, selective inhibition of COX-2, but not COX-1, blocked PGI2 production under low cholesterol conditions. Addition of exogenous cholesterol induces dose-dependent reductions in endothelial COX-2 expression as measured by reverse transcription-polymerase chain reaction and by Western blotting. Pretreatment of cells with actinomycin D, a transcription inhibitor, reduced COX-2-derived PGI2 production by 45.9% (from 0.55+/-0.09 to 0.25+/-0.08 ng/mL). Taken together, these observations indicate that endothelial PGI2 production is regulated by cholesterol at the transcriptional level and that cholesterol-sensitive transcriptional pathways that regulate COX-2 expression are present in vascular tissue.

MeSH Terms (17)

Aspirin Cells, Cultured Cholesterol Cholesterol, LDL Cyclooxygenase 1 Cyclooxygenase 2 Dose-Response Relationship, Drug Endothelium, Vascular Enzyme Inhibitors Epoprostenol Humans Isoenzymes Membrane Proteins Prostaglandin-Endoperoxide Synthases RNA, Messenger Transcription, Genetic Umbilical Veins

Connections (2)

This publication is referenced by other Labnodes entities: